Literature DB >> 35849309

Impact of temporalis muscle thickness in elderly patients with newly diagnosed glioblastoma treated with radio or radio-chemotherapy.

Francesco Pasqualetti1,2, Michela Gabelloni3, Alessandra Gonnelli4, Lorenzo Faggioni3, Martina Cantarella4, Sabrina Montrone4, Giovanni Gadducci4, Noemi Giannini4, Nicola Montemurro5, Roberto Mattioni4, Paolo Perrini5, Riccardo Morganti6, Mirco Cosottini7, Emanuele Neri3, Fabiola Paiar4.   

Abstract

BACKGROUND: There is an unmet need for new biomarkers able to predict both the outcomes of up-front therapy and the compliance of elderly patients diagnosed with glioblastoma. For this purpose, temporal muscle thickness is a promising tool to be investigated.
METHODS: Data from 52 glioblastoma patients older than 65 years, treated with post-operative radio or radio-chemotherapy and referred to Pisa University Hospital, were retrieved. The thickness of temporal muscle (TMT) was divided into quartiles and correlated with overall survival (Our primary endpoint). Survival curves were calculated using Kaplan-Meier method, and log-rank test was used to evaluate the differences between curves.
RESULTS: Patients in the lower quartile of TMT, with TMT thinner than 7 mm, have survived longer; both univariate and multivariate analyses showed a statistically significant correlation between TMT and overall survival (P = 0.012 and P = 0.003, respectively).
CONCLUSION: Future prospective and more extensive studies focused on elderly glioblastoma patients are needed to confirm the role of TMT as prognostic value on OS and to help explaining this association.
© 2022. Italian Society of Medical Radiology.

Entities:  

Keywords:  Elderly patients; Elderly patients with glioblastoma; Geriatric oncology sarcopenia; Glioblastoma; Glioblastoma biomarkers; Radiotherapy; Temporalis thickness

Mesh:

Year:  2022        PMID: 35849309     DOI: 10.1007/s11547-022-01524-2

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   6.313


  14 in total

1.  Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.

Authors:  Julia Furtner; Els Genbrugge; Thierry Gorlia; Martin Bendszus; Martha Nowosielski; Vassilis Golfinopoulos; Michael Weller; Martin J van den Bent; Wolfgang Wick; Matthias Preusser
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

2.  Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).

Authors:  Giuseppe Lombardi; Andrea Pace; Francesco Pasqualetti; Simona Rizzato; Marina Faedi; Elena Anghileri; Elisa Nicolotto; Elena Bazzoli; Luisa Bellu; Veronica Villani; Alessandra Fabi; Patrizia Ferrazza; Lorena Gurrieri; Monia Dall'Agata; Marica Eoli; Alessandro Della Puppa; Ardi Pambuku; Domenico D'Avella; Franco Berti; Roberta Rudà; Vittorina Zagonel
Journal:  J Neurooncol       Date:  2015-09-30       Impact factor: 4.130

3.  Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.

Authors:  Hee Seung Lee; Si Young Kim; Moon Jae Chung; Jeong Youp Park; Seungmin Bang; Seung Woo Park; Si Young Song
Journal:  Nutr Cancer       Date:  2019-04-07       Impact factor: 2.900

4.  Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.

Authors:  Riccardo Muglia; Matteo Simonelli; Federico Pessina; Emanuela Morenghi; Pierina Navarria; Pasquale Persico; Elena Lorenzi; Angelo Dipasquale; Marco Grimaldi; Marta Scorsetti; Armando Santoro; Letterio S Politi
Journal:  Eur Radiol       Date:  2020-11-17       Impact factor: 5.315

5.  A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme.

Authors:  G S Bauman; L E Gaspar; B J Fisher; E C Halperin; D R Macdonald; J G Cairncross
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-07-01       Impact factor: 7.038

6.  Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience.

Authors:  Francesco Pasqualetti; Patrizia Ferrazza; Paola Cocuzza; Lucia Fatigante; Giuseppe Pasqualetti; Maria Grazia Fabbrini; Fabio Monzani
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

7.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

8.  Basic and Translational Advances in Glioblastoma.

Authors:  Sara G M Piccirillo; Marta M Alonso; Francesco Pasqualetti
Journal:  Biomed Res Int       Date:  2018-03-26       Impact factor: 3.411

Review 9.  The Skeletal Muscle as an Active Player Against Cancer Cachexia.

Authors:  Fabio Penna; Riccardo Ballarò; Marc Beltrà; Serena De Lucia; Lorena García Castillo; Paola Costelli
Journal:  Front Physiol       Date:  2019-02-18       Impact factor: 4.566

Review 10.  EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

Authors:  Michael Weller; Martin van den Bent; Matthias Preusser; Emilie Le Rhun; Jörg C Tonn; Giuseppe Minniti; Martin Bendszus; Carmen Balana; Olivier Chinot; Linda Dirven; Pim French; Monika E Hegi; Asgeir S Jakola; Michael Platten; Patrick Roth; Roberta Rudà; Susan Short; Marion Smits; Martin J B Taphoorn; Andreas von Deimling; Manfred Westphal; Riccardo Soffietti; Guido Reifenberger; Wolfgang Wick
Journal:  Nat Rev Clin Oncol       Date:  2020-12-08       Impact factor: 66.675

View more
  1 in total

1.  Association between Temporal Muscle Thickness and Overall Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis.

Authors:  Young Il Kim; Ja Young Shin; Seung Ho Yang; Hyun Ho Kim; Byoung Yong Shim; Stephen Ahn
Journal:  Curr Oncol       Date:  2022-09-08       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.